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Obesity is a global epidemic that is causally associated with a range of diseases, including type 2 diabetes and cardiovascular disease, at
the population-level. However, there is marked heterogeneity in obesity-related outcomes among individuals. This might reflect geno-
type-dependent responses to adiposity. Given that adiposity, measured by BMI, is associatedwithwidespread changes in gene expression
and regulatory variants mediate the majority of known complex trait loci, we sought to identify gene-by-BMI (G3 BMI) interactions on
the regulation of gene expression in a multi-tissue RNA-sequencing (RNA-seq) dataset from the TwinsUK cohort (n ¼ 856). At a false
discovery rate of 5%, we identified 16 cisG3 BMI interactions (top cis interaction:CHURC1, rs7143432, p¼ 2.03 1012) and one variant
regulating 53 genes in trans (top trans interaction: ZNF423, rs3851570, p ¼ 8.2 3 1013), all in adipose tissue. The interactions were ad-
ipose-specific and enriched for variants overlapping adipocyte enhancers, and regulated genes were enriched for metabolic and inflam-
matory processes. We replicated a subset of the interactions in an independent adipose RNA-seq dataset (deCODE genetics, n¼ 754). We
also confirmed the interactions with an alternate measure of obesity, dual-energy X-ray absorptiometry (DXA)-derived visceral-fat-vol-
ume measurements, in a subset of TwinsUK individuals (n ¼ 682). The identified G 3 BMI regulatory effects demonstrate the dynamic
nature of gene regulation and reveal a functional mechanism underlying the heterogeneous response to obesity. Additionally, we have
provided a web browser allowing interactive exploration of the dataset, including of association between expression, BMI, and G3 BMI
regulatory effects in four tissues.Introduction
Obesity (MIM: 601665) is a global epidemic that has been
robustly associated with a range of co-morbidities such as
cardiovascular disease, insulin resistance, type 2 diabetes
(T2D [MIM: 125853]), and increased risk of certain types
of cancer.1,2 However, at the individual level, co-morbidity
development among obese individuals is heterogeneous,
suggesting that genetics and adiposity might interact to
mediate downstream disease and complex trait develop-
ment.3 The existence of gene-by-adiposity interactions
on complex traits is supported by twin studies demon-
strating that BMI modifies the heritability of co-morbid
traits such as blood pressure and insulin sensitivity.4,5
Obesity manifests as excess adipose tissue and has a
systemic effect on bodily function. BMI-associated genetic
variants are enriched for hypothalamic processes,6 which
suggests that the variants that cause obesity exert their ef-
fects primarily in the brain. In contrast, variants for many
obesity co-morbid traits are primarily thought to regulate
genes active in certain peripheral tissues, such as adipose,
muscle, and the liver (insulin resistance),7 the heart and
endothelial cells (QT-interval, which is predictive of cardio-
vascular disease),8 and adipose (body-fat distribution ),9 for
example. Therefore, BMI could influence co-morbidity
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variants active in those tissues.
Gene-by-environment (G 3 E) interactions have been
identified extensively in model organisms,10–13 but identi-
fying G 3 E interactions on complex traits in humans has
proven to be difficult due to the need to obtain accurately
measured environmental exposures and large sample
sizes. In contrast, studies of G 3 E effects on the regula-
tion of gene expression, often termed context-specific
expression quantitative trait loci (eQTL) analyses, have
been more successful and can capture environments
that act on the cellular, tissue, or organismal level. Regu-
latory G 3 E effects have been discovered for various en-
vironments, including age and sex,14 in vivo and ex vivo
treatment response,15–18 and tissue and/or cell of resi-
dence.19,20 Twin studies agnostic to the underlying
environment have also identified G 3 E regulatory vari-
ants.21,22 Most genetic variants identified through
genome-wide association studies (GWASs) are thought to
be regulatory variants; thus, utilizing gene expression to
identify gene-by-environment interactions is a promising
strategy for identifying factors that interact with disease-
relevant regulatory variation.22 Because 60% of disease-
associated eQTLs are tissue dependent, it is critical to
study the genetic regulation of expression in the appro-
priate disease-relevant tissues.23on, London SE1 7EH, UK; 2Department of Genetic Medicine and Develop-
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In this study, we considered BMI as a physiological envi-
ronment and conduct a genome-wide search for gene-by-
BMI (G 3 BMI) interactions on the regulation of gene
expression by utilizing a multi-tissue (adipose, skin,
whole blood, and lymphoblastoid cell lines [LCLs]) RNA-
sequencing (RNA-seq) dataset including data collected
from 856 healthy female twins. We first demonstrated
that BMI has a pervasive effect on gene expression in pe-
ripheral tissues and that the strongest effects are observed
in adipose tissue. We then identified 16 significant cis
G 3 BMI interactions (false discovery rate [FDR] ¼ 5%)
on the regulation of gene expression in adipose tissue
and we provide evidence of replicated examples in an inde-
pendent adipose tissue cohort (deCODE, n ¼ 754). The
G 3 BMI regulatory interactions are adipose specific and
are enriched for metabolic and inflammatory pathways.
By extending the analysis in trans we were able to identify
one cis G3 BMI variant that regulates the expression of 53
genes in trans in a BMI-dependent manner. Regulatory in-
teractions such as these will have increasingly important
utility in characterizing the functionality and context
specificity of genetic variation discovered via traditional
GWAS approaches. To enable exploration of our results,
we have developed an interactive website that allows re-
searchers to model and plot data in real-time (see the
Web Resources). Using this service, users can investigate
genes and SNPs of interest for G 3 BMI effects and explore
the relationship between BMI and exon-level expression in
four separate tissues.Material and Methods
Sample Collection
The study included 856 healthy female twins who are a part of the
TwinsUK registry and are all of European ancestry. Punch biopsies
of subcutaneous adipose tissue from a photo-protected area of the
stomach adjacent and inferior to the umbilicus were obtained
from consenting individuals. Skin from the punch biopsy was
then dissected to separate it from adipose tissue, and both samples
were weighed and immediately frozen with liquid nitrogen. Pe-
ripheral-blood samples were also collected as part of the study,
and LCLs were generated via transformation of the B-lymphocyte
fraction with Epstein-Barr virus (EBV). The European Collection of
Cell Cultures agency performed the transformation process. All
the procedures followed were in accordance with the ethical stan-
dards of the St. Thomas Research Ethics Committee (reference 07/
H0802/84) at St. Thomas Hospital in London. Volunteers gave
informed consent and signed a consent form before the biopsy
procedure. Volunteers were supplied with an appropriate detailed
information sheet regarding the research project and biopsy pro-
cedure by post before attending the biopsy.Genotyping and Imputation
Genome-wide SNP data for the TwinsUK individuals were gener-
ated as previously described.6,25,26 In short, TwinsUK samples
were genotyped on a combination of platforms (HumanHap300,
HumanHap610Q, and 1M-Duo Illumina arrays). Quality control
and merging of the array datasets has previously been described568 The American Journal of Human Genetics 99, 567–579, Septembin detail.25 The cleaned data were pre-phased with IMPUTE2
with no reference panel and were then imputed into the 1000 Ge-
nomes phase 1 reference panel (interim, data freeze accessed
November 10, 2010; the 1000 Genomes Project Consortium
2012).27 Variants with an INFO score >0.8 on all platforms and
a MAF >5% were retained for analysis.
Phenotype Collection
Height, weight, and visceral fat volume were measured at the time
of biopsy. Visceral fat volume was measured via dual-energy X-ray
absorptiometry (DXA; Hologic QDR 4500 Plus), according to the
standard manufacturer’s protocol.
RNA-Seq
RNA-seq data were generated as previously described.22 In brief,
samples were prepared for sequencing with the unstranded Illu-
mina TruSeq sample preparation kit and sequenced on a HiSeq
2000 machine. The 49 bp paired-end reads were aligned to the
UCSC Genome Browser GRCh37 reference genome with the Bur-
rows-Wheeler Aligner.28 GENCODE v.10 was used to annotate
genes. Samples were excluded if they failed to have more than
10 million reads map to known exons or if the sequence data
did not correspond to actual genotype data.
Exon Quantification and Normalization
To quantify exons, all overlapping exons of a gene were merged
into one meta-exon. We counted reads as mapping to a given
meta-exon if either of its start or end coordinates overlapped a
meta-exon boundary. All read-count quantifications were cor-
rected for variation in sequencing depth between samples by
normalizing the number of reads to the median number of well-
mapped reads. We only used exons that were quantified in more
than 90% of the individuals. Exon expression values were rank-
based inverse normal transformed for downstream analysis.
Transcriptome-wide Association Analysis
To determine whether expressed exons were associated to a
phenotype of interest (BMI/visceral fat), each exon was treated
as a quantitative trait in a linear mixed-effects model implemented
with the lme4 package.29 Phenotypic data were treated as contin-
uous independent traits. A full model with the phenotype fitted
(Model 1) was compared to a null model in which the samemodel
was fitted but the phenotype (BMI) was omitted. These models
were compared with a one-degree-of-freedom ANOVA. All known
technical variables were included as covariates in the model. To
model the twin structure in our data, we included two multi-level
indicator variables, termed family and zygosity, as random effects
in the model. These variables are coded as follows: if individuals i
and j are co-twins, we code familyi ¼ familyj, if individuals i and j
are monozygotic co-twins, we code zygosityi ¼ zygosityj, and if
they are dizygotic co-twins, we code zygosityi s zygosityj. The
zygosity term captures the increased genetic relatedness within
an MZ twin pair as compared to a DZ twin pair. If individuals i
and j are unrelated, familyi s familyj and zygosityi s zygosityj.
We estimated a FDR within each tissue by using the package
‘‘qvalue’’30 to obtain q values that correspond to a FDR of 5%.
Model 1 is as follows:
yi  Xbþ Zuþ ε; (Model 1)
where yi is the i
th non-PEER (probabilistic estimation of expression
residuals)-corrected exon expression vector. X is a designmatrix ofer 1, 2016
fixed effects: phenotype (BMI or visceral fat), age, age squared,
mean GC content, and insert size mode. Z represents all random
effects: primer index, batch (blood only), family, and zygosity. ε
is a residual error term representing unaccounted for variation in
expression.
cis G 3 BMI Interaction Discovery
Expression residuals corrected for family structure and technical
variables and 50 PEER31 factors were used to identify G 3 BMI in-
teractions in all four tissues. Each exon was tested for a SNP3 BMI
interaction (Model 2) with all SNPs within 1 Mb of the transcrip-
tion start site. The interaction test was implemented with the
‘‘modellinear_cross’’ function in the Matrix eQTL R package.32
Model 2 is as follows:
y  Iþ bAþ bA2 þ bP þ bSNP þ bP 3 SNP þ ε; (Model 2)
where y ¼ expression, I ¼ intercept, A ¼ age, A2 ¼ age squared, P ¼
phenotype (BMI), SNP ¼ allele dosage, and ε ¼ residual error.
Correction for Hidden Confounders
A common approach when performing eQTL mapping has been
to adjust expression profiles for unknown latent variables. The
aim is to capture hidden factors that confound gene expression
measurements, such as unmeasured technical variables (e.g., batch
effects). However, these methods can also capture biological fac-
tors, and thus, depending on the analysis performed, might not
be appropriate. We utilized PEER, a Bayesian method similar to
surrogate variable analysis, which has been shown to increase
the ability to detect genetic and interaction effects threefold.31
We calculated latent factors by applying PEER to expression resid-
uals that had been corrected for family structure and technical
variables. PEER was run using no additional covariates and ac-
counting for mean expression. In adipose tissue, three of the first
five PEER factors were significantly correlated to BMI (jrmaxj ¼
0.52, p ¼ 1.2 3 1051, Figure S1). We used PEER-corrected data
for cis G 3 BMI interaction analysis, but not for direct association
of BMI with expression levels or for trans G 3 BMI interaction
analysis (see below). Removing BMI-associated PEER factors max-
imizes the ability to discover interactions with BMI byminimizing
model co-linearity (Figures S1 and S2). It has also been demon-
strated that removing latent factors, even those highly correlated
with the environment of interest, results in the discovery of signif-
icantly more interactions on gene expression.20
FDR Estimation
The FDR for calling an interaction significant was estimated based
on an approximated permutation strategy as previously described
and implemented.33,34 Expression residuals were calculated in
which all main effects (BMI, SNP, and age) were regressed out.
Expression values were permuted for each exon while preserving
genotype structure. The interaction-term (BMI3 SNP) significance
was calculated for each exon. All p values were stored to calculate a
genome-wide FDR. Because genes vary in the number of exons
they are composed of, separate FDRs were calculated by classifying
genes based on a similar number of exons, determined from the
distribution of exons expressed in each tissue. A 5% FDR was
calculated by computing the ratio of permuted test statistics
more significant to the observed interactions, divided by the num-
ber of permutations performed (n ¼ 100). All interactions with a
corrected FDR p value <0.05 were classified as significant and
taken forward for replication.The Americantrans G 3 BMI Discovery
Given that cis effects are enriched for trans effects and we were
underpowered to perform a genome-wide trans-interaction anal-
ysis, we utilized a two-step procedure to identify trans G 3 BMI
interactions in adipose tissue. We first repeated the cis G 3 BMI
scan as described above, using expression residuals corrected
for family structure and known technical variables but not
corrected for PEER factors. PEER correction removes broadly
acting variance components, including the effects of multi-
gene trans-regulators, and is therefore not appropriate for trans
eQTL analysis. The resulting four significant non-PEER-corrected
cis G 3 BMI variants (rs1464171, rs3851570, rs113368712
and rs35662778; FDR ¼ 5%) were then tested for trans G 3
BMI effects. Trans effects were tested for all genes at a distance
greater than 5 MB from the variant or on a different chromo-
some. Trans G 3 BMI significance was assessed with a strict Bon-
ferroni correction, accounting for testing four variants against
116,643 exons and corresponding to a p value threshold of
1.1 3 107.deCODE Replication Cohort
The replication cohort consists of 754 RNA-seq subcutaneous adi-
pose samples obtained from Icelandic individuals, all of whom
had imputed genotypes, as previously described.35 The sample
set is comprised of 333 males and 421 female participants with
an age 47 5 14 (mean 5 SD) and BMI 30 5 6.6. RNA-seq reads
were aligned to Homo sapiens build 38 (UCSC Genome Browser)
with TopHat36 v.2.0.12 with a supplied set of known transcripts
in GTF format (RefSeq, NCBI). TopHat was configured such that
it first attempts to align reads to the provided transcriptome,
then, for reads that do not map fully to the transcriptome, it at-
tempts to map them onto the genome. Overlapping exons were
merged into one meta-exon. Fragments were counted if they map-
ped to a meta-exon and if either read in the pair had the start or
end (aligned) coordinate overlapping a meta-exon boundary. We
excluded exons that had zero fragment counts for more than
90% of individuals. Counts were normalized for number of reads
mapped and exon lengths and were rank normal transformed.
The following covariates were used to correct for technical differ-
ences in the RNA experiments: average fragment length, exonic
rate, number of genes detected, number of mapped read pairs,
number of alternative alignments, and percentage of reads origi-
nating from coding bases (PCT), along with 50 inferred hidden
factors which were evaluated with PEER. The technical RNA-seq
quality metrics were gathered with the CollectRnaSeqMetrics
tool in Picard v.1.79 and RNA-SeQC v.1.1.6.37Replication Analysis
The 16 cis G 3 BMI interactions (FDR ¼ 5%) were taken forward
for replication in deCODE. 13 genes were available in the deCODE
dataset. The two datasets were called with different genome builds
and gene annotation sets, preventing simple mapping of meta-
exons.We thus used liftover to map the TwinsUKmeta-exon coor-
dinates from GrCh37 to GrCh38 (UCSC Genome Browser) and
defined corresponding meta-exons as those with more than a
90% overlap in length in both annotation sets. This strategy iden-
tified corresponding meta-exons for eight genes (CHURC1 [MIM:
608577], CIDEA [MIM: 604440], ZNF117 [MIM: 194624], PEPD
[MIM: 613230], ANXA5 [MIM: 131230], HLA-DQB2 [MIM:
615161], IFNAR1 [MIM: 107450], and SCFD2). An additional three
genes (ADH1A [MIM: 103700], SPAG17 [MIM: 616554], andJournal of Human Genetics 99, 567–579, September 1, 2016 569
ERV3-1 [MIM: 131170]) had a partial overlap, ranging from 33%–
85%, with a deCODE meta-exon Two genes (PHACTR3 [MIM:
608725] and CAST [MIM: 114090]) had minimal overlap of 4%
with a deCODE meta-exon, indicating the meta-exon does not
represent an analogous quantification. Given that multiple
TwinsUK PHACTR3 meta-exons were significant, and the second
most significant TwinsUK meta-exon (chr20: 58,349,298–
58,349,545, p value ¼ 1.7 3 108 in TwinsUK) exactly overlapped
a deCODE meta-exon, we used the meta-exon corresponding to
the second TwinsUK signal for the replication analysis of
PHACTR3. Exact meta-exon coordinates are provided in Table
S1. Given the low annotation overlap at CAST (4%), we tested
all CAST exons for replication and corrected for the number of
exons tested in deCODE (30). The three genes unavailable for rep-
lications were RP11-71E19.1, which was not present in the RefSeq
gene annotation used by deCODE, POU6F2 (MIM: 609062), which
did not pass quality control in deCODE (low expression), and SIK1
(MIM: 605705), which was quantified, but the corresponding SNP
rs12482956 and proxies were unavailable in the deCODE
imputation.
Integration with GWAS
Overlap of the 16 G 3 BMI lead SNPs with GWAS variants was
determined by searching the National Human Genome Research
Institute (NHGRI) database (accessed June 19, 2015) for each
SNP or proxy SNPs (r2 > 0.6). The database was filtered to include
only genome-wide significant loci. We tested the overlap identi-
fied at ADH1A for colocalization by implementing the regulatory
trait concordance (RTC) method.53 The RTC score assesses evi-
dence for causality by testing whether the effect of a GWAS SNP
abrogates the effect of an eQTL while accounting for the local
linkage disequilibrium (LD) structure of the locus. All SNPs with
MAF> 5%were in the window 100.1–100.6 Mb, a 250 kb window
centered on the index SNP tested. For each of the 1,129 variants,
we fitted an interaction (Model 3) and main effect (Model 4)
model:
ADH1A expression  BMI3 SNPN þ BMI3 rs1693457
(Model 3)
and
ADH1A expression  SNPN þ BMI3 rs1693457; (Model 4)
where SNPN is SNP1–SNP1,129.
The results were then ranked by increasing significance of the
interaction p value (BMI3 rs1693457), and RTC scores were calcu-
lated as follows:
RTC ¼ NSNPs  RankGWAS SNP
NSNPs
(Equation 1)
where NSNPs ¼ number of SNPs tested.
RankGWAS_SNP ¼ the rank of the GWAS SNP in the full list of
ordered test statistics.
Tissue Specificity and eQTL p1 Analysis
To determine the tissue specificity of identified G 3 BMI
interactions and whether they are enriched for main-effect
eQTLs, p1 analysis was performed.
30 p0 is a measure for esti-
mating the proportion of true null hypotheses. 1  p0 ¼ p1
can therefore be used to measure the proportion of significant
(true) associations. The significant exon-SNP pairs from adipose
tissue were matched to the same exon-SNP pair in each of the570 The American Journal of Human Genetics 99, 567–579, Septembother tissues, and a p1 value was estimated with the R package
‘‘qvalue’’30. The same method was used to determine whether
the significant G 3 BMI interactions are enriched for main-effect
eQTLs.
Gene Set Enrichment
Both cis and trans gene set enrichment analysis data were analyzed
through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA).
Input consists of the gene list of interest, and to correctly control
for background genes, we used all genes expressed in our adipose
tissue expression datasets as a reference to compare against.
Benjamini-Hochberg corrected p values were calculated as speci-
fied by Ingenuity. The macrophage-enriched metabolic network
(MEMN) gene membership was tested for G 3 BMI enrichment
via p1 analysis, as above.
Trans-Network Mediation Analysis
Significant mediation was determined by computing Sobel’s test
statistic.38 To calculate the mediation score, the following four
models and equations were implemented:
y  b1Aþ b2A2 þ b3P þ b4Gþ b5P3Gþ ε; (Model 5)
y  b1Eþ b2Aþ b3A2 þ b4P þ b5Gþ b6P3Gþ ε; (Model 6)
Mediation score ¼ bM5 5  bM6 6
bM5 5
; (Equation 2)
and
Z ¼ bM5 53 bM6 6ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2M6 63 S
2
M5 5 þ b2M5 53 S2M6 6
q ; (Equation 3)
where y ¼ trans gene expression, A ¼ age, A2 ¼ age squared, E ¼ cis
gene expression, P¼ BMI, andG¼ cis genotype. M5_5 is the inter-
action coefficient from Model 5. M6_6 is the interaction coeffi-
cient from Model 6. S2 is the SE of each interaction coefficient.
By conditioning on cis gene expression (the mediator, E) we can
determine whether each individual interaction detected in trans is
regulated in cis or is independent by quantifying DbP 3 G (Equa-
tion 2). We can test the significance of this change by using Sobel’s
test statistic (Equation 3).
Roadmap Epigenomics Functional Element
Enrichment Analysis
To investigate enrichment of cell-type-specific enhancers,
HaploReg v.4 was utilized.39 HaploReg takes a list of SNPs and
uses a binomial test for enhancer enrichment in different cell
types based on the SNP of interest (G 3 BMI SNP) and any
SNPs that are in high LD with the lead SNP (r2 > 0.8). These
SNPs are then compared to a background that consists of the
common variants (5%) obtained from the 1000 Genomes Proj-
ect. Enhancer annotation was obtained from the ChromHMM
15-state model.
Interactive Website
The website was designed with RMarkdown, custom CSS, and a
shiny backend server for real-time statistical analysis. All models
implemented are those described above, with additional options
given to users to allow the choice of covariate inclusion and/or
PEER correction.er 1, 2016
Figure 1. BMI Is Highly Associated with Gene Expression in Multiple Tissues
p value distribution of association between BMI and expression of all measured exons in each tissue.Results
BMI Has a Pervasive Effect on Gene Expression
To characterize the effect of BMI on the transcriptome, we
utilized a multi-tissue RNA-seq dataset including data from
856 healthy female twins in the TwinsUK cohort.22 Partic-
ipants were 38–84 years old (median ¼ 60) with a BMI
range of 16–47 (median ¼ 25) at the time of biopsy
(Figure S3). As described previously,22 after quality control,
RNA-seq data and imputed genotypes from the 1000 Ge-
nomes phase 1 reference panel were available for 720 sub-
cutaneous adipose tissue samples, 672 skin samples, 765
LCLs, and 368 whole-blood samples. All analysis was based
on exon-level quantifications with 16,149 to 18,229 genes
expressed per tissue (Table S2).
We first assessed the extent of association between BMI
and gene expression in all four tissues (adipose, skin,
blood, and LCLs). BMI has a strong influence on expres-
sion in each of the primary tissues, but little to no effect
in LCLs; with a FDR of 5%, 16,818 genes, 9,216 genes,
6,640 genes, and zero genes had at least one exon associ-
ated with BMI in adipose, skin, blood, and LCLs
respectively (Figure 1). We assessed the tissue specificity
of the associations by using p1 estimates (Figure S4).
Approximately half of the associations detected in adipose
were observed in the other two primary tissues (skin p1 ¼
0.53, blood p1¼ 0.54), whereas adipose captured over 75%
of the associations detected in skin (p1 ¼ 0.78) and blood
(p1 ¼ 0.76). There was no enrichment for shared effects
in LCLs (p1 ¼ 0 for all tissues), which is consistent with a
lack of LCL expression and whole-body trait associations
seen for multiple traits,21 suggesting the transformation
process or subsequent cell culture has removed the in vivo
physiological environmental effects captured by profiling
primary tissue. Our estimates of a pervasive and tissue-spe-
cific influence of BMI on expression are consistent with
previous estimates from microarrays40 and confirm that
BMI acts as a strong physiological influence on gene
expression. Full summary statistics for the association be-
tween BMI and exon-level expression in all four tissues
can be found at our website (see Web Resources).The AmericanIdentification of cis G 3 BMI Regulatory Variants
To identify BMI-dependent regulatory effects, we per-
formed a global cis scan for G 3 BMI eQTLs in each tissue
by using PEER-corrected expression residuals. Significant
G 3 BMI effects (FDR ¼ 5%) were called with a per-tis-
sue FDR, determined by permutation (see Material and
Methods). Our FDR method ensures we penalize against
genes with more exons given that, statistically, they are
more likely to show association by chance. We identified
16 G 3 BMI regulatory effects in adipose (Table 1,
Table S3, Figure 2) and none in the other three tissues.
The 16 genes regulated by a G 3 BMI effect in adipose
are ADH1A, ANXA5, CAST, CHURC1, CIDEA, ERV3-1,
HLA-DQB2, IFNAR1, PEPD, PHACTR3, SCFD2, SPAG17,
and ZNF117. 12 of the 16 G 3 BMI variants also had
a significant main effect (eQTL) on adipose expression
when tested without the interaction term (Table 1,
Table S3).
We sought replication in an independent dataset of
subcutaneous adipose tissue biopsies (Icelandic cohort,
deCODE genetics, n¼ 754), which included quantification
of 13 of the 16 genes. Because TwinsUK and deCODE used
different alignment strategies, genome builds, and gene
annotation versions, some exons did not directly map be-
tween the two datasets. We identified corresponding exons
with a greater than 90%overlap in annotation in bothdata-
sets forninegenes (Table S1).Of thesenine, threewere repli-
cated and eight showed a consistent direction of effect be-
tween the studies (Figure 3A). The replicated genes were
PEPD (pTwinsUK ¼ 4.8 3 1010, pdeCODE ¼ 4.2 3 106),
PHACTR3 (pTwinsUK ¼ 1.6. 3 108, pdeCODE ¼ 1.1 3 104),
and CHURC1 (pTwinsUK ¼ 2.0 3 1012, pdeCODE ¼ 8.5 3
104) (Table 1). Another four genes showed partial overlap
with a deCODE exon: ERV3-1 (85% overlap), SPAG17
(69% overlap), ADH1A (33% overlap), and CAST (4%
overlap). None of these replicated and only CAST had a
consistent direction of effect, with p ¼ 0.053. Given the
low annotation overlap at CAST (4%), we examined all
other CAST exons in deCODE, and the exon in chr5:
96,076,448–96,076,487 was associated in a consistent
direction at nominal significance (p ¼ 0.001, p ¼ 0.03Journal of Human Genetics 99, 567–579, September 1, 2016 571
Table 1. Significant cis G 3 BMI Regulatory Interactions in Adipose, FDR ¼ 5%
Gene SNP EA EAF TwinsUK b
TwinsUK
p Value deCODE b deCODE p Value
Main-effect eQTL
(FDR ¼ 1%) Enhancer
CHURC1 rs7143432 A 0.78 0.026 2.0 3 1012 0.011 8.5 3 104 adipose, skin, blood, LCLs –
CAST rs13160562 G 0.69 0.032 3.9 3 1012 0.004 0.053a adipose, skin, blood, LCLs adipocyte
CIDEA rs7505859 C 0.62 0.028 3.1 3 1011 0.004 0.21 adipose, skin adipocyte
ZNF117 rs6948760 T 0.40 0.039 4.4 3 1011 0.0009 0.79 adipose, skin, blood, LCLs –
ADH1A rs1693457 C 0.18 0.034 5.9 3 1011 0.0015 0.85a adipose adipocyte
RP11-71E19.1 rs1980140 A 0.79 0.058 6.1 3 1011 NA NA adipose adipocyte
PEPD rs10415555 A 0.81 0.044 4.8 3 1010 0.014 4.2 3 106 adipose, skin adipocyte
ANXA5 rs2306420 G 0.71 0.022 1.4 3 109 0.001 0.52 adipose, skin, blood, LCLs adipocyte
SIK1 rs12482956 A 0.71 0.058 3.0 3 109 NA NA – blood
HLA-DQB2 rs114370295 T 0.27 0.050 3.5 3 109 0.004 0.45 adipose –
ERV3-1 rs11979998 C 0.52 0.032 8.4 3 109 0.0008 0.84a adipose, skin, blood, LCLs blood
POU6F2 rs34792397 G 0.75 0.041 9.9 3 109 NA NA adipose –
IFNAR1 rs2834098 C 0.78 0.047 1.4 3 108 0.002 0.58 – stem cells
SCFD2 rs7687982 A 0.75 0.059 1.5 3 108 0.006 0.26 – aMSC
PHACTR3 rs6070866 G 0.51 0.044 1.7 3 108 0.020 1.1 3 104 adipose brain
SPAG17 rs9661038 G 0.64 0.043 2.8 3 108 0.004 0.083a – –
Exact exon coordinates are listed in Tables S1 and S3. The main-effect column lists the TwinsUK tissues where the listed gene-SNP pair has a main-effect cis eQTL
when tested without the interaction effect (a dash denotes no eQTL in any tissue). All interaction effects were adipose specific. If a SNP or its proxy (r2 > 0.8) falls
within an enhancer as defined by ENCODE, the cell type that enhancer is primarily active in is listed in the Enhancer column. EA, effect allele; EAF, effect-allele
frequency in the TwinsUK discovery sample.
adeCODE exons with less than 90% overlap with the corresponding deCODE exon (see methods, Table S1).corrected for 30 CAST exons). Overall, the replication dem-
onstrates the robustness of our findings and the discovery
and independent replication of regulatory variants whose
effects are influenced by adiposity.
Tissue Specificity of G 3 BMI Regulatory Effects and
Expression
The G 3 BMI regulatory effects are highly tissue specific.
None of the 16 G 3 BMI interaction effects are present in
the other TwinsUK tissues (Table S3). Although 11 G 3
BMI regulated genes showed multi-tissue expression, five
genes (PHACTR3, ADH1A, RP11-71E19.1, POU6F2, and
SPAG17) have adipose-specific expression within TwinsUK
but no detectable expression in blood, skin, or LCLs. The
G3 BMI variants are enriched for tissue-specific regulatory
potential; we tested the 16 variants for enrichment in
enhancer activity in the 127 Roadmap Epigenomics cell
types and found an enrichment only in purified adipocytes
(mesenchymal-stem-cell-derived adipocytes, p ¼ 0.028).
Nine G 3 BMI variants disrupt specific or multiple
transcription factor binding motifs, and eight SNPs or
their proxies (r2 > 0.8) have a significant evolutionary
GERP conservation score (Table S3). The tissue specificity
of G 3 BMI effects, expression of the genes they act on,
and regulatory annotation of the G 3 BMI variants high-
lights the importance of studying gene regulation in the
appropriate tissue for a disease of interest.572 The American Journal of Human Genetics 99, 567–579, SeptembG 3 BMI Regulatory Variants and Genes Link to
Related Traits
Wenext investigated links between the G3 BMI genes and
variants and related traits. CAST (calpastatin) is a ubiqui-
tously expressed endogenous inhibitor of the calpains
(calcium-dependent cysteine proteases). The calpastatin-
calpain system has been extensively implicated in cardiac
remodeling and heart failure and has been proposed as a
potential therapeutic target for heart disease.41 CAST is
implicated in modulating the immune response in certain
cell types,42 including inhibition of macrophage hyperac-
tivation under inflammatory conditions,43 which could
be linked to the varying degrees of systemic inflammation
seen in obese individuals.
Another intriguing signal is at PEPD (peptidase D).
PEPD’s function is the recycling of proline, and it has
also been shown to be essential for collagen production.
Variants intronic to PEPD are associated with T2D, adipo-
nectin, triglyceride levels, and fasting insulin;44–47 how-
ever, the lead GWAS SNPs are in low LD with the G 3
BMI regulatory variant (r2 ¼ 0.145, D0 ¼ 1). PEPD’s link
to T2D and adiponectin, although not fully understood,
is interesting in the light of BMI’s relationship with T2D
development and adiponectin regulation.
CIDEA (cell death activator) function has been studied
extensively in model organisms, and CIDEA-knockout
mice show higher basal metabolic rates, lipolysis, ander 1, 2016
Figure 2. Example of Three FDR ¼ 5%
Significant Adipose cis G 3 BMI Regula-
tory Interactions
The vertical axis represents expression of a
given gene and the horizontal axis repre-
sents BMI. Each point represents an indi-
vidual. Each plot is split on allele dosage
to show how the relationship between
expression and BMI is dependent on geno-
type (OA, other allele; EA, effect allele; cor-
responding variants and alleles are listed in
Table 1). A change in the slope of the asso-
ciation between BMI and expression asso-
ciation across genotypic classes indicates
a genotype-dependent response to BMI,
or G 3 BMI interaction. For example,
CHURC1 expression decreases with BMI
in individuals homozygous for the effect
allele, but increases with BMI in other
allele homozygotes regardless of the
mean change in gene expression (main-ef-
fect eQTL).higher core body temperatures.48 Mice without functional
copies of CIDEA are resistant to both diet-induced obesity
and T2D.49,50 Similar evidence has been observed in hu-
mans.51 In our data, CIDEA expression has a strong nega-
tive correlation with BMI (p value ¼ 8.1 3 1054). How-
ever, individuals with the minor allele of rs7505859
show the opposite relationship (CIDEA is positively corre-
lated with BMI). Again, this is an interesting relationship
in the light of BMI’s contribution to T2D development.
We integrated the 16 G 3 BMI variants with the NHGRI
database of GWASs to determine whether the G3 BMI reg-
ulatory effects are linked to common traits or disease.
A proxy SNP (rs1229977, r2 ¼ 0.63) for the G 3 BMI
variant regulating ADH1A (alcohol dehydrogenase 1A),
rs1693457, is associated with esophageal cancer (MIM:
133239) in a large GWAS.52 The GWAS association at this
locus covers several ADH family genes; however, we
show that, in addition to the G 3 BMI effect, rs1693457
is a main-effect eQTL (b ¼ 0.89, p ¼ 2.9 3 1041) for
ADH1A. To formally test for colocalization between the
regulatory variant and the GWAS signal, we implemented
the regulatory trait concordance method (RTC).53 The
esophageal cancer GWAS SNP (rs1229977) had an RTC
score of 0.98 when tested with either the interaction or
main-effect model, indicating that the regulatory and
GWAS signals are tagging the same underlying variant.
There is prior evidence for a G 3 E interaction at
rs1229977—the association to esophageal cancer is modi-The American Journal of Human Genefied by alcohol consumption.52 Given
the complicated links between BMI,
alcohol intake, and smoking, it is
possible that BMI is acting as a proxy
for correlated external environmental
factors at this locus, which could
also explain the lack of replication of
the ADH1A G 3 BMI effect in theIcelandic data, given that external environments can
vary between countries.
Detection of trans G 3 BMI Effects in Adipose Tissue
Evidence frommodel organisms suggests that trans (distal)
regulatory variants are more likely to mediate the effects of
the environment and are thus strong candidates for G 3 E
interaction effects.10 In contrast to cis eQTLs, trans eQTLs
have been difficult to identify in humans because of
smaller effect sizes and the increased burden of multiple
testing in a genome-wide scan. Given that cis eQTLs are en-
riched for trans-eQTL effects,54 we utilized a two-step strat-
egy to identify transG3 BMI interactions in adipose tissue,
first identifying cis G 3 BMI interactions and then testing
the identified cisG3 BMI variants for transG3 BMI effects
with all adipose-expressed exons. For trans discovery, both
steps were performed with non-PEER-corrected expression
residuals because correction for latent factors can remove
broadly acting trans effects. This strategy identified four
cis G 3 BMI variants (Table S4), one of which, rs3851570
(cis G 3 BMI interaction on ALG9 expression [MIM:
606941], p value ¼ 2.03 108), is associated with 53 genes
in trans (Bonferroni corrected p value threshold of p <
1.1 3 107) (Figure 4A, Table S5, Figure S5).
IPA of the 53 genes in the ALG9 G 3 BMI trans-network
revealed enrichment for inhibition of matrix metallopro-
teases (Benjamini-Hochberg corrected p ¼ 3.6 3 108),
oxidative phosphorylation (Benjamini-Hochberg correctedtics 99, 567–579, September 1, 2016 573
A B C
Figure 3. Replication, Location, and Validation of cis G 3 BMI Interactions
(A) Comparison of G 3 BMI interaction coefficients (FDR ¼ 5%) in the TwinsUK discovery (horizontal axis) and deCODE replication
dataset (vertical axis). 9 out of 13 interactions show a consistent direction of effect across cohorts.
(B) The lead G 3 BMI SNPs all cluster at the TSS. Location of the lead SNPs for the 127 G 3 BMI interactions with p < 106 are plotted
with respect to the TSS of the corresponding gene. Lead SNPs for the 26 significant G3 BMI interactions (FDR¼ 5%) are labeled with the
corresponding gene name.
(C) Comparison of p values of G3 BMI interaction andG3 visceral-fat interaction for the same SNP gene pairs. All 127 interactions with
G 3 BMI p < 106 are plotted. All 16 G 3 BMI (FDR ¼ 5%) show a G 3 visceral-fat interaction, three of which increased 2–5 orders of
magnitude in despite the smaller sample size in the visceral fat analysis (n ¼ 682).p ¼ 3.1 3 104), and gene membership of a cardiovascular
disease network (Figure 4B), indicating that BMI-dependent
regulatory effects at rs3851570 have a wide-ranging role in
metabolism and structural remodeling of adipose tissue.
ALG9 itself catalyzes lipid-linked oligosaccharide assembly
in the N-glycan biosynthesis pathway. Statistical mediation
analysis supports amediator role ofALG9 expression in regu-
lation of the trans G 3 BMI network (Sobel’s mediation
pvalue%0.001,Table S6) (seeMaterial andMethods).Given
that ALG9 has no known regulatory role on transcription,
the regulation of the trans genes most likely functions via
regulation of signaling cascades or other complex indirect
processes. We note that the most significant trans G 3 BMI
gene is the transcription factor ZNF423 (p ¼ 8.2 3 1013)
(Figure 4C). ZNF423 regulates pre-adipocyte determination
and expression of PPARG (MIM: 601487), a master regulator
of adipocyte differentiation,55 and could be a candidate for
mediating the widespread trans effect, although this would
require further investigation. We investigated the trans G3
BMI effect in a second population by testing rs3851570
against all measured exon expression amounts (n ¼
168,951) in the deCODE dataset. Although the 53 trans
genes did not replicate in the deCODE dataset, transcrip-
tome-wide we see a significant enrichment for low p values
(p1¼ 0.14), demonstrating that rs3851570 has broad effects
on adipose gene expression in a BMI-dependent manner in
multiple populations. This is consistent with previous
studies, wherein transcriptome-wide regulatory behavior of
the multi-gene trans variants replicate across cohorts but
the top genes associated with such trans networks do not.23
General Properties of cis G 3 BMI Regulatory Effects
and Variants
To investigate the common properties of G 3 BMI regula-
tory effects and the genes they act upon, we next focused574 The American Journal of Human Genetics 99, 567–579, Septembon the 127 adipose G3 BMI cis effects that passed a relaxed
threshold of p< 1.03 106 (Table S7). All 127 G3 BMI in-
teractions show an opposite direction of effect between
expression and BMI in the two-homozygote classes (for
example, PHACTR3, Figure 2). This high prevalence of
opposing direction of effect most likely reflects our power
to detect opposing effects rather than the true distribution.
Consistent with main-effect eQTL variants, G 3 BMI vari-
ants are enriched for proximity to the transcription start
site, most noticeably when looking at genome-wide
significant G 3 BMI variants (median distance, 38 kb)
(Figure 3B). The 127 G3 BMI variants show significant ad-
iposemain effects when tested without an interaction with
BMI (number of eQTLs (FDR ¼ 1%): adipose ¼ 20, blood ¼
8, LCLs ¼ 10, and skin ¼ 10) (Figure S6). Whereas main-
effect eQTL enrichment was observed in other tissues,
the G 3 BMI effect is adipose-tissue specific, with p1 ¼
0.038 in skin and p1 ¼ 0 in blood and LCLs. G 3 BMI
variants are not directly associated with BMI, and no sig-
nificant enrichment was seen in a BMI GWAS of 339,224
individuals6 (p1 ¼ 0), suggesting the G 3 BMI effects are
not the result of indirectly measured gene-by-gene effects.
G 3 BMI Are Enriched for Key Metabolic Processes
To elucidate the biological consequences of BMI-dependent
regulation, we investigated the 127 genes regulated by a
G3BMI interaction at p< 1.03106 for functional enrich-
ment byusing IPA. The 127 genes are enriched for keymeta-
bolic processes, including LXL and RXR activation (p ¼
6.13103) anduptakeof cholesterol (p¼9.13105) (Table
S8). LXL and RXR are part of the insulin-signaling pathway
and are the target of severalwidely used T2Dmedications.56
Additionally, the 127 genes are enriched for the antigen-
presentation pathway (p ¼ 2.0 3 104) and quantity of
macrophages (p ¼ 5.8 3 103). We do not see evidence forer 1, 2016
Figure 4. rs3851570 Has a trans G 3 BMI Effect on 53 Genes
(A) Circos plot displaying the location of rs3851570 and trans G 3 BMI associations. Each line represents a trans association originating
from rs3851570. Green lines indicate a positive beta, and red lines represent a negative beta. The outer circle delineates chromosomes,
including cytogenetic bands.
(legend continued on next page)
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G 3 BMI effects in the BMI-associated MEMN of co-ex-
pressed adipose genes.40,57 The 553 MEMN genes show no
enrichment for G 3 BMI effects (p1 ¼ 0.021), and there is
not a significant overlap between the 127 G 3 BMI genes
and MEMN genes (binomial p ¼ 0.78). However, we do
note that of the four G 3 BMI genes in the MEMN
(ICAM3 [MIM: 146631], TBX3 [MIM: 601621], CIDEA,
and ADH1A), two do have genome-wide-significant G 3
BMI effects (CIDEA and ADH1A).BMI Accurately Captures the Effects of Adiposity
BMI is an easily measured anthropometric trait that is
commonly used as a surrogate for overall adiposity. It has
been noted that BMI can potentially misclassify an indi-
vidual as obese, for example, when a subject has a large
lean-muscle mass (typical of athletes). Additionally, BMI
measurements do not capture differences in body-fat dis-
tribution. Fat accumulation in the abdominal region,
particularly of visceral fat, is predictive of multiple adverse
health outcomes independent of overall BMI.58 We thus
sought to validate our G 3 BMI findings by performing
the same analysis on a subset of the TwinsUK cohort that
had DXA-measured abdominal visceral fat volume. Within
this subset (n ¼ 682), visceral fat ranges from 78 to 1,542 g
(mean ¼ 627 g) and, as expected, broadly correlates with
BMI (Figure S7). All 16 G 3 BMI interactions (FDR ¼ 5%)
showed a similar effect in the G 3 visceral fat analysis,
and despite the drop in sample size, some interactions
increased in significance by four orders of magnitude
(CAST p ¼ 3.0 3 1016, PEPD p ¼ 3.0 3 1015)
(Figure 3C), potentially due to the increased sensitivity
gained from an accurate machine-measured phenotype.
This provides evidence that G 3 BMI can capture real
adiposity effects and suggests that, although more difficult
to obtain, power to detect interactions increases dramati-
cally with phenotypic measurement accuracy, such as in
measurements obtained by DXA.Discussion
Here, we describe the pervasive effect BMI has on periph-
eral-tissue gene expression and identify robust examples
of BMI-dependent regulatory variants. We characterize the
properties of G 3 BMI regulatory variants, showing that
they typically have strongmain effects and are highly tissue
specific. Additionally, we identify a G 3 BMI interaction
that regulates an adipose-specific trans-network of 53 genes.
Although twin and family studies estimate that ~60% of(B) Trans genes are enriched formembership in a cardiovascular diseas
network. Genes highlighted in red are present in the trans-network, an
represent their regulatory relationship. Solid lines represent direct evid
evidence. The shape of each node denotes the gene’s primary known
(C) A signal plot of the most significant G 3 BMI trans-association
expression of ZNF423 and the horizontal-axis is BMI. Each point rep
according to their allele dosage for SNP rs3851570.
576 The American Journal of Human Genetics 99, 567–579, Septembexpression heritability acts in trans,23,24 trans effects have
beendifficult to identify inhumans.Given thehighcontext
specificity of trans effects in model organisms,10 trans eQTL
discovery efforts in humans might be more fruitful when
accounting for environmental interactions.
These findings suggest that identifying G 3 E interac-
tions on gene expression is possible with significantly
smaller sample sizes, compared to complex traits. How-
ever, we note that the current study is underpowered,
and we expect more G 3 BMI interactions to be identified
with larger sample sizes. Extrapolating from empirical
investigation of the power to detect cell-type-specific inter-
actions in whole-blood transcriptomes,20 we expect that
power to detect G3 BMI effects on expression should scale
linearly with sample size. Increasing sample size will most
likely necessitate combining data across populations,
which can confound G3 E analysis if the environment dif-
fers across study populations. Using a physiological vari-
able such as BMI should mitigate this caveat, however,
we acknowledge that BMI could also be acting as a surro-
gate for a highly correlated cofactor, such as diet, which
might vary across populations and thus complicate replica-
tion or meta-analysis efforts. Body-fat traits have been
shown to be sexually dimorphic. It is therefore important
to point out that although we demonstrated replicated
examples of G 3 BMI effects in a separate adipose tissue
cohort, the discovery sample was an all-female cohort,
whereas 44% of the replication cohort were men, poten-
tially reducing our replicative power.
It is well documented that increasing BMI induces
changes in the cell-type composition and inflammation
of adipose tissue.59–63 Changes in cell-type composition
could be the underlying mechanism of some of our identi-
fied G 3 BMI interactions. This is an intriguing possibility,
and we are actively investigating methods to deconvolve
cell-type expression data from whole-tissue expression
profiles to address this. Enrichment for G 3 BMI genes in
immune response pathways could also represent a change
in the activation state of cells already present in adipose
tissue or in the genetic control of inflammation suscepti-
bility that takes place under weight gain, during which
some individuals, due to their genotype, could undergo
less inflammation in an obese state. Given the enrichment
for genes involved in metabolic processes, other poten-
tial mechanism include BMI-driven changes in meta-
bolism,64 adipocyte size65 (a consequence of having to
store more lipid droplets in an obese state),66 increased
vascularization as a result of hypoxia,67 and changes in
overall energy expenditure.68e network (IPA). Plot displays all genes in the cardiovascular disease
d non-trans network genes are shown in gray. Lines between genes
ence of interaction,while dashed lines indicate indirect interaction
function (protein kinase, transcription factor, complex, etc).
to rs3851570, at the gene ZNF423. The vertical axis represents
resents an individual; individuals are grouped into the three boxes
er 1, 2016
Discovery of G 3 BMI effects on gene expression has
broad applicability. Characterization of G 3 BMI regula-
tory variants and the genes they act upon will help eluci-
date the downstream consequences of obesity and the
molecular pathways leading to associated diseases. Similar
to the widespread use of main-effect eQTLs to interpret
GWAS loci, context-specific eQTLs can be used both to
identify the molecular mechanism of GWAS loci and to
identify relevant, interacting environments or risk factors.
To facilitate this, we havemade the full results of this study
freely available in an interactive web service. Finally, iden-
tifying individuals whose genotypes predispose them to
BMI-specific outcomes could enable targeted interventions
for those most likely to respond and could improve accu-
racy in assessing genotypic risk of obesity-related diseases.Accession Numbers
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